# A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

> **NCT03367403** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 272 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Placebo
- **DRUG:** LY3202626

## Key facts

- **NCT ID:** NCT03367403
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2020-12-04
- **Final completion:** 2021-09-21
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367403, "A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03367403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*